Antibody-drug conjugate · Inhibitor of DNA topoisomerase I (TOP1) · developed by Pfizer
ApprovedFDA, Jun 1996
1Registered trials
What is Liposomal irinotecan?
Liposomal irinotecan is a liposomal formulation of irinotecan, a camptothecin derivative that binds the topoisomerase I-DNA complex and prevents religation of DNA single-strand breaks, leading to double-strand DNA damage. It is used in the treatment of pancreatic ductal adenocarcinoma.
Summary written with AI from the sources listed at the end of this page.
Metastatic carcinoma of the colon or rectum (Camptosar)
Metastatic pancreatic adenocarcinoma (Onivyde)
From the indications section of the FDA label (version of May 12, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.